Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779058 | 1.00 | SLC15A1 (0.53) | SLC15A1ALDH1A1CTSLCTSBCTSS | |
| SCHEMBL353327 | 1.00 | SLC15A1 (0.53) | SLC15A1ALDH1A1CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL7331174 | 0.98 | SLC15A1 (0.52) | SLC15A1ALDH1A1CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL19808961 | 0.98 | SLC15A1 (0.52) | SLC15A1ALDH1A1CTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL7331177 | 0.98 | SLC15A1 (0.52) | SLC15A1ALDH1A1CTSLCTSBCTSS | |
| Alcohol SCHEMBL28299003 | 0.95 | SLC15A1 (0.50) | SLC15A1ALDH1A1CTSLCTSBCTSS | |
| Phenylalanine SCHEMBL10663101 | 0.89 | SLC7A5 (0.56) | SLC15A1ALDH1A1CTSLCTSBCTSS | |
| SCHEMBL27552079 | 0.88 | SLC15A1 (0.49) | SLC15A1ALDH1A1CTSLCTSBCTSS | |
| SCHEMBL6711118 | 0.88 | SLC15A1 (0.49) | SLC15A1ALDH1A1CTSLCTSBCTSS | |
| SCHEMBL31171285 | 0.87 | IARS1 (0.46) | SLC15A1KMT2AMEN1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102250202-B | 1-paranitrophenyl-beta-carboline-3-formyl amine acid carbamates and synthesis method and use thereof | UNIV CAPITAL MEDICAL SCIENCES | 2013-08-28 | — | — | CN | claimed |
| CN-102241693-B | N,N'-di-(1-methyl-beta-carboline-3-formyl)-lysly aminoacid benzyl esters, synthetic method thereof and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2013-08-28 | — | — | CN | claimed |
| CN-102241674-B | Synthesis method and antitumor activity evaluation of 1,1-dimethyl-beta-carboline-3-formacyl amino acid benzyl ester | UNIV CAPITAL MEDICAL | 2012-09-12 | — | — | CN | claimed |
| CN-101906102-B | Beta-carboline alkaloid derivative, preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-08-29 | — | — | CN | claimed |
| CN-102250202-A | 1-paranitrophenyl-beta-carboline-3-formyl amine acid carbamates and synthesis method and use thereof | UNIV CAPITAL MEDICAL | 2011-11-23 | — | — | CN | claimed |
| CN-102241674-A | Synthesis method and antitumor activity evaluation of 1,1-dimethyl-beta-carboline-3-formacyl amino acid benzyl ester | UNIV CAPITAL MEDICAL | 2011-11-16 | — | — | CN | claimed |
| CN-102241693-A | N,N'-di-(1-methyl-beta-carboline-3-formyl)-lysly aminoacid benzyl esters, synthetic method thereof and application thereof | UNIV CAPITAL MEDICAL | 2011-11-16 | — | — | CN | claimed |
| CN-101497615-B | Substituted purine, preparation and use in medicine | ZHEJIANG MED XINCHANG PHARM | 2010-12-15 | — | — | CN | claimed |
| CN-101906102-A | Beta-carboline alkaloid derivative, preparation method and application thereof | UNIV CAPITAL MEDICAL | 2010-12-08 | — | — | CN | claimed |
| CN-100572382-C | The chemical sproof heterogeneous ring compound of reversing tumor cell, its preparation method and application | UNIV CAPITAL MEDICAL (CN) | 2009-12-23 | — | — | CN | claimed |
| CN-101597289-A | 2-tryptophyl-beta-tetrahydro carboline-3-formyol amino-acid benzyl ester and its production and application | UNIV CAPITAL MEDICAL (CN) | 2009-12-09 | — | — | CN | claimed |
| CN-101597290-A | β-Ka Lin-3-formyl tryptophyl amino-acid benzyl ester and its production and application | UNIV CAPITAL MEDICAL (CN) | 2009-12-09 | — | — | CN | claimed |
| CN-101497615-A | Substituted purine, preparation and use in medicine | XINCHANG PHARMACEUTICAL FACTORY ZHEJIANG MEDICINE CO LTD (CN) | 2009-08-05 | — | — | CN | claimed |
| CN-101239979-A | Heterocyclic compound capable of inversing tumor cell drug tolerance, preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES (CN) | 2008-08-13 | — | — | CN | claimed |
| US-20240083846-A1 | SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-03-14 | — | — | US | disclosed |
| EP-4262763-A1 | SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | Council of Scientific & Industrial Research (IN) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022130411-A1 | SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-06-23 | — | — | WO | disclosed |
| EP-0668856-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1995-08-30 | — | — | EP | disclosed |
| US-5326773-A | Prodrug enzyme inhibitors | MERCK & CO., INC. (US) | 1994-07-05 | — | — | US | disclosed |
| WO-1994010137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083846-A1 | SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | BIRC5, BIRC2, BIRC3 | SLC15A1 3059/4885ALDH1A1 4373/4885CTSL 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.